Business Context and Reporting Period
Company: Alkermes Plc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2025
Reporting Period: Event-based report regarding clinical trial results announced on November 12, 2025.
Key Financial Metrics
This filing is a current report regarding a clinical trial event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event reported is the announcement of positive topline results from the randomized, double-blind treatment period of the Vibrance-2 study. This Phase 2 study evaluated the safety and efficacy of alixorexton (formerly ALKS 2680) compared to placebo in patients with narcolepsy type 2.
Guidance, Outlook, and Management Commentary
- Management Commentary: The Company characterized the topline results from the Vibrance-2 study as "positive."
- Investor Communication: Alkermes hosted an investor webcast and conference call to present the results. A presentation detailing these results is included as Exhibit 99.2.
- Regulatory Disclosure: The press release and presentation are furnished under Regulation FD (Item 7.01) and are not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Outlook: No specific financial guidance or future operational outlook is provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific statistical data supporting the "positive" characterization of the Vibrance-2 results.
- Examine Exhibit 99.2 (Investor Presentation) for detailed efficacy and safety endpoints of alixorexton in narcolepsy type 2.
- Verify the regulatory implications of these Phase 2 results for future Phase 3 trial planning or potential FDA interactions.
- Check subsequent filings for any updates on the commercial or strategic impact of these results on the Company's pipeline valuation.